SanegeneBio Joins Forces with Eli Lilly for RNAi Research
SanegeneBio, a pioneering clinical-stage biotechnology firm specializing in RNAi therapeutics, has embarked on an exciting global collaboration with Eli Lilly and Company to explore innovative treatments for metabolic diseases. This partnership is set to leverage SanegeneBio's cutting-edge LEAD™ technology, designed for specialized tissue-selective delivery.
Collaboration Aims at Revolutionary Therapeutics
The collaboration will center on the discovery and advancement of RNAi candidates aimed at addressing various metabolic disorders. SanegeneBio will spearhead the discovery process, focusing on identifying optimized LEAD™-based RNAi molecules tailored for each specific program. Upon successful discovery, Eli Lilly will take the reins for subsequent IND-enabling studies, clinical trials, and the eventual commercialization of these promising treatments.
Impact of LEAD™ Technology on Patient Care
SanegeneBio’s LEAD™ platform exhibits the potential to develop groundbreaking therapies that can be administered subcutaneously as infrequently as twice yearly. This could significantly improve the management of metabolic conditions, enhancing patient convenience and adherence to treatment regimens.
Company's Vision for the Future
Weimin Wang, the Chief Executive Officer and Founder of SanegeneBio, expressed enthusiasm about the partnership, stating, "Partnering with Lilly validates our innovative LEAD™ platform for delivering RNAi therapies." The collaboration combines SanegeneBio’s innovative approach to RNAi with Lilly’s expertise and leadership in metabolic disease innovation, creating a dynamic force to transform patient care.
Financial Aspects of the Collaboration
Under their agreement, SanegeneBio will receive an upfront payment along with equity investment, along with eligibility for milestone payments in the near future. The collaboration holds the potential for SanegeneBio to earn up to $1.2 billion tied to discovery, development, regulatory milestones, and commercial success, with additional tiered royalties on future product sales.
About SanegeneBio
Founded in 2021, SanegeneBio is at the forefront of RNAi therapeutic development, backed by notable venture capital. With R&D operations across Boston, Shanghai, and Suzhou, the company is driven by a vision that RNAi technology can lead to successful treatments across various therapeutic areas, thereby improving patients' quality of life globally. Current projects in their expanding pipeline encompass experimental drugs targeting autoimmune diseases, obesity, and cardiometabolic conditions, with several clinical trials already underway for new therapeutic options.
Frequently Asked Questions
What is the collaboration between SanegeneBio and Eli Lilly focused on?
The collaboration focuses on developing RNAi therapeutics for metabolic diseases using SanegeneBio's LEAD™ delivery technology.
What is LEAD™ technology?
LEAD™ stands for Ligand and Enhancer Assisted Delivery, which aims for tissue-selective delivery of RNAi medicines, enhancing therapeutic effectiveness.
How will the collaboration progress?
SanegeneBio will lead discovery efforts while Eli Lilly will handle clinical development and commercialization efforts following the discovery phase.
What financial benefits is SanegeneBio expecting from this collaboration?
SanegeneBio anticipates upfront payments, milestone payments up to $1.2 billion, and royalties from future product sales.
What is SanegeneBio's mission?
SanegeneBio aims to innovate RNAi therapies that can provide transformative health solutions and improve patient quality of life.
